Table 2. Preoperative application of ICIs in LT.
| Authors | Year | No. of patients | ICIs | Mean immunotherapy course | Immunosuppression | Mean time between immunotherapy and LT | Rejection | Recurrence |
| ICI, immune checkpoint inhibitor; LT, liver transplantation; MMF, mycophenolate mofetil; Tac, tacrolimus; ATG, anti-thymocyte globulin; N, No; Y, Yes; N/A, not available. | ||||||||
| Schwacha-Eipper et al. (26) | 2020 | 1 | Nivolumab | 34 | N/A | 6 weeks | N | N |
| Chen et al. (45) | 2021 | 5 | Nivolumab | 3 | Tac, MMF | 9 weeks | N | 2/5 Y |
| Kang et al. (46) | 2021 | 1 | Pembrolizumab | 3 | Sirolimus, Tac | 138 d | N | N |
| Dehghan et al. (47) | 2021 | 1 | Nivolumab | 17 | Steroids, MMF, Tac | 5 weeks | Y | N/A |
| Abdelrahim et al. (48) | 2022 | 1 | Atezolizumab | 6 | Tac, MMF | 8 weeks | N | N |
| Dave et al. (49) | 2022 | 5 | Nivolumab | N/A | N/A | 105 d | 2/5 Y | N/A |
| Sogbe et al. (50) | 2021 | 1 | Durvalumab | N/A | Steroids, MMF, Tac | >3 months | N | N |
| Schnickel et al. (51) | 2022 | 5 | Nivolumab | N/A | Steroids, MMF, Tac | 14.6 months | 2/5 Y | N |
| Tabrizian et al. (52) | 2021 | 9 | Nivolumab | 13 | Steroids, MMF, Tac | 40.8 months | 1/9 Y | N |
| Lizaola-Mayo et al. (53) | 2021 | 1 | Ipilimumab Nivolumab | N/A | Tac, MMF, ATG, steriods | 9 weeks | N | N |
| Chen et al. (54) | 2021 | 1 | Toripalimab | 10 | Tac, steroids | 93 d | Y | N/A |
| Qiao et al. (55) | 2021 | 7 | Pembrolizumab Camrelizumab | 3 | Basiliximab, steroids, cyclosporine, Tac, sirolimus, MMF | 1.3 months | 1/7 Y | N/A |
| Nordness et al. (60) | 2020 | 1 | Nivolumab | 44 | Steroids, MMF, Tac | 8 d | Y | N/A |
| Aby et al. (61) | 2022 | 1 | Nivolumab | 23 | Steroids, MMF, Tac | 16 d | Y | N/A |